title: [Phase II trial with cystemustine (60 mg/m2) in advanced or metastatic pretreated lung carcinoma].
abstract: From January 1990 to November 1994, 23 patients with advanced pretreated lung carcinoma were enrolled into a phase II trial to test a new nitrosourea, cystemustine, given every 2 weeks at the dose of 60 mg/m(2) in a 15-minute IV infusion. All eligible patients were considered evaluable for response and toxicity (WHO criteria).
authors.affiliation: Centre Léon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France.
authors.forename: P
authors.initials: P
authors.lastname: Rebattu
authors.forename: B
authors.initials: B
authors.lastname: Coudert
authors.forename: M
authors.initials: M
authors.lastname: Schneider
authors.forename: R
authors.initials: R
authors.lastname: Ouabdesselam
authors.forename: M
authors.initials: M
authors.lastname: Lentz
authors.forename: A
authors.initials: A
authors.lastname: Hanauske
authors.forename: B
authors.initials: B
authors.lastname: Chevallierdagger
authors.forename: P
authors.initials: P
authors.lastname: Fumoleau
authors.forename: P
authors.initials: P
authors.lastname: Chollet
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009607:Nitrosourea Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D010166:Palliative Care
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C051263:N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea